Cargando…

Phosphatidylinositol 3-Kinase Mediates Bronchioalveolar Stem Cell Expansion in Mouse Models of Oncogenic K-ras-Induced Lung Cancer

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in Western countries. Developing more effective NSCLC therapeutics will require the elucidation of the genetic and biochemical bases for this disease. Bronchioalveolar stem cells (BASCs) are a putative ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yanan, Iwanaga, Kentaro, Raso, Maria Gabriela, Wislez, Marie, Hanna, Amy E., Wieder, Eric D., Molldrem, Jeffrey J., Wistuba, Ignacio I., Powis, Garth, Demayo, Francesco J., Kim, Carla F., Kurie, Jonathan M.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2376060/
https://www.ncbi.nlm.nih.gov/pubmed/18493606
http://dx.doi.org/10.1371/journal.pone.0002220
Descripción
Sumario:BACKGROUND: Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in Western countries. Developing more effective NSCLC therapeutics will require the elucidation of the genetic and biochemical bases for this disease. Bronchioalveolar stem cells (BASCs) are a putative cancer stem cell population in mouse models of oncogenic K-ras-induced lung adenocarcinoma, an histologic subtype of NSCLC. The signals activated by oncogenic K-ras that mediate BASC expansion have not been fully defined. METHODOLOGY/PRINCIPAL FINDINGS: We used genetic and pharmacologic approaches to modulate the activity of phosphatidylinositol 3-kinase (PI3K), a key mediator of oncogenic K-ras, in two genetic mouse models of lung adenocarcinoma. Oncogenic K-ras-induced BASC accumulation and tumor growth were blocked by treatment with a small molecule PI3K inhibitor and enhanced by inactivation of phosphatase and tensin homologue deleted from chromosome 10, a negative regulator of PI3K. CONCLUSIONS/SIGNIFICANCE: We conclude that PI3K is a critical regulator of BASC expansion, supporting treatment strategies to target PI3K in NSCLC patients.